[go: up one dir, main page]

WO1997000072A1 - Composition anti-inflammatoire/analgesique - Google Patents

Composition anti-inflammatoire/analgesique Download PDF

Info

Publication number
WO1997000072A1
WO1997000072A1 PCT/JP1996/001614 JP9601614W WO9700072A1 WO 1997000072 A1 WO1997000072 A1 WO 1997000072A1 JP 9601614 W JP9601614 W JP 9601614W WO 9700072 A1 WO9700072 A1 WO 9700072A1
Authority
WO
WIPO (PCT)
Prior art keywords
ibuprofen
acetaminophen
inflammatory
composition according
inflammatory analgesic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1996/001614
Other languages
English (en)
Japanese (ja)
Inventor
Ichiro Okudaira
Kenji Tsunoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to AU60160/96A priority Critical patent/AU6016096A/en
Publication of WO1997000072A1 publication Critical patent/WO1997000072A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Definitions

  • the present invention relates to an anti-inflammatory analgesic composition having enhanced analgesic activity.
  • Oxaprozin is widely used as an anti-inflammatory analgesic, but its action is relatively weak, and it is said that it is difficult to obtain a sufficient effect on respiratory diseases.
  • the analgesics ibuprofen and acetaminophen are effective for respiratory diseases such as common cold syndrome. Had a problem.
  • U.S. Pat. No. 4,552,8999 describes a pharmaceutical composition for treating respiratory diseases such as common cold, which contains anti-inflammatory agents such as ibuprofen and oxabrogine. I have.
  • the pharmaceutical composition produces a synergistic effect by combining an anti-inflammatory agent with a sympathomimetic stimulant, an antihistamine, and the like, and does not suggest a synergistic effect due to the combination of the anti-inflammatory agents.
  • a pharmaceutical composition containing oxaboxazin and ibubrofen or acetoaminophen Disclosure of the invention
  • An object of the present invention is to provide an anti-inflammatory analgesic having an enhanced analgesic effect.
  • the present inventors have conducted studies with the aim of enhancing the analgesic effect.
  • the combination of oxaprozin with the analgesic agent ibuprofen or acetaminophen provides an anti-inflammatory analgesic with enhanced analgesic action. This has led to the completion of the present invention.
  • the present invention includes the following inventions.
  • An anti-inflammatory analgesic composition comprising oxasuboral gin and ibubrofen as active ingredients.
  • composition according to (2) wherein the mixing ratio (weight ratio) of oxabrozin: ibuprofen is 1: 0.1 to 1:10.
  • composition according to (2), wherein the mixing ratio (weight ratio) of oxabrozin: ibuprofen is 0.25 to 1: 5.
  • An anti-inflammatory analgesic composition containing oxasubatin and acetoaminophen as active ingredients.
  • composition according to (5), wherein the compounding ratio (heavy Mit) of oxaprozin: acetaminophen is 1: 0.1 to 1: 1.
  • composition according to the above (5), wherein the mixing ratio (weight ratio) of oxabrozine: acetaminophen is from 1: 0.25 to 1: 5.
  • a method for treating a respiratory disease which comprises administering the anti-inflammatory analgesic composition according to the above (1) to a patient with a respiratory disease.
  • the mixing ratio (weight ratio) of oxabrozine: ibubrofen or acetoaminophen is usually 1: 0.1-1: 10, preferably 1: 0.25: L: 5.
  • the anti-inflammatory analgesic composition of the present invention can usually be orally administered to an adult at 300 to 1600 mg per day as an active ingredient in one or several divided doses. This dose can be appropriately adjusted depending on the age, weight, and medical condition.
  • an auxiliary drug such as an antitussive, an anti-inflammatory enzyme, a sympathomimetic, an anti-inflammatory, a drowsiness inhibitor, a vitamin, a crude drug, or an antacid may be appropriately added.
  • the anti-inflammatory analgesic composition of the present invention is used as a formulation for oral administration such as tablets, granules, powders, capsules and solutions. These preparations can be prepared by a conventional method.
  • Carriers used in the preparation of preparations include excipients such as lactose, starch, sugar, mannitol, crystalline cellulose, binders such as hydroxypropylcellulose, hydroxypropyl xymethylcellulose, gelatin, PVP, There are disintegrants such as calcium cellulose cellulose and low-substituted hydroxypropylcellulose, and lubricants such as magnesium stearate, hydrogenated castor oil, and talc. Dyes, flavoring agents and the like can be used.
  • No. 2 hard capsule was filled in 200 mg each to obtain 5000 capsules.
  • the obtained mixed powder was filled into No. 2 hard capsules in an amount of 20 mg each to obtain 6000 capsules.
  • the anti-inflammatory analgesic composition of the present invention has an enhanced analgesic effect as compared to a case where (a) oxabrozine or (b) ibuprofen or acetaminophen is used alone, and includes a power syndrome and the like. Since it has an effect on respiratory diseases, it can be used as a cold remedy. In addition, since a synergistic effect is observed, the effect can be obtained at a low dose, thereby reducing side effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composition anti-inflammatoire/analgésique qui comporte en tant qu'ingrédients actifs (a) de l'oxaprozine et (b) de l'ibuprofène ou de l'acétaminophène. Comparée aux cas où soit (a) l'oxaprozine, soit (b) l'ibuprofène ou l'acétaminophène est employé seul, la présente composition présente un effet analgésique amélioré et est efficace contre les maladies du système respiratoire telles que le syndrome de refroidissement, ce qui permet de l'utiliser en tant que remède contre le rhume.
PCT/JP1996/001614 1995-06-16 1996-06-13 Composition anti-inflammatoire/analgesique Ceased WO1997000072A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60160/96A AU6016096A (en) 1995-06-16 1996-06-13 Anti-inflammatory/analgetic composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14982195 1995-06-16
JP7/149821 1995-06-16

Publications (1)

Publication Number Publication Date
WO1997000072A1 true WO1997000072A1 (fr) 1997-01-03

Family

ID=15483440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1996/001614 Ceased WO1997000072A1 (fr) 1995-06-16 1996-06-13 Composition anti-inflammatoire/analgesique

Country Status (2)

Country Link
AU (1) AU6016096A (fr)
WO (1) WO1997000072A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010089913A (ko) * 2000-03-13 2001-10-17 류영선 무공해 완구신소재 및 그 제조공법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BY THE PHARMACIST SOCIETY OF OSAKA HOSPITAL, "Drug Handbook (5th Edit.)", YAKUGYO JIHOSHA CO., LTD., 5 February 1995, p. 126-127, 108-109, 94-95. *
THE MERCK INDEX, Eleventh Edition (1989) p. 6880, 4811, 39. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010089913A (ko) * 2000-03-13 2001-10-17 류영선 무공해 완구신소재 및 그 제조공법

Also Published As

Publication number Publication date
AU6016096A (en) 1997-01-15

Similar Documents

Publication Publication Date Title
JPS6143112A (ja) 精神性欲機能障害治療剤
US4590213A (en) Anti-anxiety method
Halpern Analgesic drugs in the management of pain
JPS59112948A (ja) コレステロ−ルレベル低下剤
JPH0157093B2 (fr)
JPH10505087A (ja) 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物
JP3170855B2 (ja) イブプロフェン含有解熱鎮痛剤
JPH0320222A (ja) 脳内虚血症治療剤
EP0748222A1 (fr) Composition antitussive contenant un antitussif et de la benzydamine
JP2006528949A5 (fr)
JP2001097856A (ja) 鎮咳剤
JP5386478B2 (ja) パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用
JP3982889B2 (ja) イブプロフェン含有医薬製剤
JPH05221857A (ja) 配合解熱鎮痛剤
JP2008100924A (ja) 総合感冒薬組み合わせ製剤
JPH0569093B2 (fr)
JPH06172187A (ja) 筋ジストロフィー症治療薬
WO1997000072A1 (fr) Composition anti-inflammatoire/analgesique
JPH083066A (ja) かぜ薬製剤
JP2000095707A (ja) 苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物
JP2006001920A (ja) 医薬製剤
JP4384435B2 (ja) くしゃみ抑制組成物
EP2727595B1 (fr) Composition pharmaceutique pour traiter l'éjaculation prématurée et procédé pour traiter l'éjaculation prématurée
JP3150642B2 (ja) 新規な抗痙攣性及び抗炎症性組成物並びにそれらの製造方法
JPH0959149A (ja) 消炎鎮痛組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA